HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nicotine Gummies Sold For Smoking Cessation Doused Under US FDA Tobacco Regulations

Executive Summary

FDA says warning to VPR Brands could be its first move to reign in sales of nicotine gummies. Statements on brand’s site could indicate sales of nicotine gummies for smoking cessation are on the rise even though the claim isn’t approved.

You may also be interested in...



GSK’s Proposal For Mouth Spray Nicorette Delayed By FDA Questions On Label

Glaxo plans to make changes FDA requested in Complete Response letter sent on 18 October, the agency’s deadline for acting on NDA for an oral spray that delivers 1 mg per spray of aqueous buffered nicotine solution for oromucosal use.

NRT Delivery Innovation Proposal In US Doesn't Deliver Expanded Indications

GSK's proposed usage for mouth spray product – reducing withdrawal symptoms, including nicotine craving – differs little from the first NRT product approved in US in 1984. Additional suggested label instructions primarily focus on stating NRTs can be used to reduce smoking or gradually stop tobacco use as opposed to quitting within a specified amount of time.

US FDA Portal Open To Receive OTC Monograph Meeting Requests

Submitting other OTC monograph program communications through CDER's NextGen Portal, including proposals to add formulations or indications to a monograph, will have to wait.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS152842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel